Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 2 Primary Myelofibrosis 1 Pancreatic Neoplasms 1 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Chronic 1 Gastrointestinal Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

Nivolumab 37 pembrolizumab 26 cabozantinib 26 Specimen Handling 23 Magnetic Resonance Spectroscopy 21 Ipilimumab 19 lenvatinib 13 belzutifan 13 Axitinib 13 CTLA-4 Antigen 10 Sunitinib 9 Radiosurgery 8 Biopsy 8 atezolizumab 7 fludarabine 4 avelumab 4 aldesleukin 4 Immunoglobulin G 4 Disulfides 4 zimberelimab 3 toripalimab 3 tivozanib 3 pazopanib 3 palbociclib 3 durvalumab 3 cemiplimab 3 Surveys and Questionnaires 3 Nephrectomy 3 Everolimus 3 Cyclophosphamide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × canakinumab × 90 days × Clear all

NCT04028245 2026-04-15

SPARC-1

Columbia University

Phase EARLY_PHASE1 Completed

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡